OCUPHIRE PHARMA INC

NASDAQ: OCUP (Ocuphire Pharma, Inc.)

Last update: 1 hour ago

1.96

0.02 (0.92%)

Previous Close 1.94
Open 1.99
Volume 16,398
Avg. Volume (3M) 153,159
Market Cap 50,754,400
Price / Sales 1.95
Price / Book 0.870
52 Weeks Range
1.50 (-23%) — 4.50 (129%)
Earnings Date 9 Aug 2024 - 13 Aug 2024
Profit Margin -85.75%
Operating Margin (TTM) -748.92%
Diluted EPS (TTM) -0.540
Quarterly Revenue Growth (YOY) -69.70%
Current Ratio (MRQ) 10.68
Operating Cash Flow (TTM) -11.46 M
Levered Free Cash Flow (TTM) -8.70 M
Return on Assets (TTM) -21.35%
Return on Equity (TTM) -36.01%

AIStockmoo Score

-3.3
Value 38% -1.7
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 38% -4.6
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 25% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money NA
Insider Activity info NA
Institutional Flow info NA
Short Interest info NA
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is near its 52-week average. Down over 5 years. info
No clear trend across the short, medium and long term. info
Levels trending up. info
Final Score -3.31

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Ocuphire Pharma, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
OCUP 51 M - - 0.870
OPT 583 M - - 4.31
CTMX - - - 1.55
ZYME - - - 7.29
PBYI - - - 2.73
ORMP - 6.74% - 0.530

Select this tab to load the latest available analysis.

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 6.11%
% Held by Institutions 8.70%

No data within this time range.

No data within this time range.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria